Reviewing SIGA Technologies (SIGA) & Osiris Therapeutics (OSIR)
SIGA Technologies (OTCMKTS: SIGA) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
This is a breakdown of recent ratings and target prices for SIGA Technologies and Osiris Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares SIGA Technologies and Osiris Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
6.7% of SIGA Technologies shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 4.7% of SIGA Technologies shares are held by company insiders. Comparatively, 44.6% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares SIGA Technologies and Osiris Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SIGA Technologies||$14.99 million||26.06||-$39.69 million||($0.53)||-9.34|
|Osiris Therapeutics||$59.87 million||3.35||-$1.78 million||($0.20)||-29.00|
Osiris Therapeutics has higher revenue and earnings than SIGA Technologies. Osiris Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
SIGA Technologies has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Osiris Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Osiris Therapeutics beats SIGA Technologies on 7 of the 9 factors compared between the two stocks.
SIGA Technologies Company Profile
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Osiris Therapeutics Company Profile
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
Receive News & Stock Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related stocks with our FREE daily email newsletter.